Direxion Daily Energy Bull 2X Shares ETF
ERX
ProShares Ultra Materials
UYM
Invesco Solar ETF
TAN
4
United States Natural Gas
UNG
5
VanEck Oil Services ETF
OIH
US Stock MarketDetailed Quotes
Cue Biopharma (CUE)
- 0.2911
- -0.0155-5.06%
Close Feb 17 16:00 ET
26.56MMarket Cap-0.71P/E (TTM)
0.3029High0.2880Low486.04KVolume0.3029Open0.3066Prev Close142.33KTurnover0.54%Turnover RatioLossP/E (Static)91.24MShares1.340052wk High2.01P/B26.39MFloat Cap0.230252wk Low--Dividend TTM90.65MShs Float31.6900Historical High--Div Yield TTM4.86%Range %0.2302Historical Low0.2920Avg Price1Lot Size
CUE Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
CUE Orderflow
Unit: --
CUE Orderflow Trend
IntradayDayWeekMonth
No Data
Cue Biopharma (CUE) News
Cue Biopharma Announces Data From CUE-401 Demonstrates All Dose Levels In Murine, NHP Trials Were Tolerated, No Adverse Events Reported
Cue Biopharma Names Lucinda Warren Chief Financial Officer
Cue Biopharma Appoints Lucinda Warren Chief Financial And Business Officer, Effective Feb. 9
Cue Biopharma: Warren Was Vice Pres of Business Development for Neuroscience and Japan at Johnson & Johnson From 2014 to 2024 >CUE
Cue Biopharma: Warren Has Served as Chief Business Officer Since Sept 2024 >CUE
Express News | Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
Cue Biopharma (CUE) Stock Forum
$Cue Biopharma (CUE.US)$ Reuters
1m
Cue Biopharma Announces Preclinical Safety and Tolerability Data for Cue-401 for the Treatment of Autoimmune and Inflammatory Diseases! Cue Biopharma Announces Data From CUE-401 Demonstrates All Dose Levels In Murine, NHP Trials Were Tolerated, No Adverse Events Reported
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells f...
1m
Cue Biopharma Announces Preclinical Safety and Tolerability Data for Cue-401 for the Treatment of Autoimmune and Inflammatory Diseases! Cue Biopharma Announces Data From CUE-401 Demonstrates All Dose Levels In Murine, NHP Trials Were Tolerated, No Adverse Events Reported
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells f...
1
$Cue Biopharma (CUE.US)$ strong buy 🚀
$Cue Biopharma (CUE.US)$ this thing gonna spike soon. money flowing in.
this what i shared in my group yesterday and this ran upto 29% today. overnight trading higher again today.
this what i shared in my group yesterday and this ran upto 29% today. overnight trading higher again today.
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)
Z3R00 : ohoooo![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")